Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


A solid-phase transfection platform for arrayed CRISPR screens.

Serçin Ö, Reither S, Roidos P, Ballin N, Palikyras S, Baginska A, Rein K, Llamazares M, Halavatyi A, Winter H, Muley T, Jurkowska RZ, Abdollahi A, Zenke FT, Neumann B, Mardin BR.

Mol Syst Biol. 2019 Dec;15(12):e8983. doi: 10.15252/msb.20198983.


Modeling the Effect of Hypoxia and DNA Repair Inhibition on Cell Survival After Photon Irradiation.

Liew H, Klein C, Zenke FT, Abdollahi A, Debus J, Dokic I, Mairani A.

Int J Mol Sci. 2019 Nov 30;20(23). pii: E6054. doi: 10.3390/ijms20236054.


Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer.

Heinrich T, Seenisamy J, Becker F, Blume B, Bomke J, Dietz M, Eckert U, Friese-Hamim M, Gunera J, Hansen K, Leuthner B, Musil D, Pfalzgraf J, Rohdich F, Siegl C, Spuck D, Wegener A, Zenke FT.

J Med Chem. 2019 Dec 26;62(24):11119-11134. doi: 10.1021/acs.jmedchem.9b01070. Epub 2019 Dec 3.


Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.

Sun Q, Guo Y, Liu X, Czauderna F, Carr MI, Zenke FT, Blaukat A, Vassilev LT.

Mol Cancer Res. 2019 Dec;17(12):2457-2468. doi: 10.1158/1541-7786.MCR-19-0362. Epub 2019 Sep 24.


Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.

Heinrich T, Seenisamy J, Blume B, Bomke J, Calderini M, Eckert U, Friese-Hamim M, Kohl R, Lehmann M, Leuthner B, Musil D, Rohdich F, Zenke FT.

J Med Chem. 2019 May 23;62(10):5025-5039. doi: 10.1021/acs.jmedchem.9b00041. Epub 2019 May 2.


A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases.

Pöhler R, Krahn JH, van den Boom J, Dobrynin G, Kaschani F, Eggenweiler HM, Zenke FT, Kaiser M, Meyer H.

Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580. doi: 10.1002/anie.201711429. Epub 2018 Jan 15.


Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.

Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, Zenke FT, Mitchison TJ.

Mol Cancer Ther. 2008 Nov;7(11):3480-9. doi: 10.1158/1535-7163.MCT-08-0684. Epub 2008 Oct 30.


p21-activated kinase 1 phosphorylates and regulates 14-3-3 binding to GEF-H1, a microtubule-localized Rho exchange factor.

Zenke FT, Krendel M, DerMardirossian C, King CC, Bohl BP, Bokoch GM.

J Biol Chem. 2004 Apr 30;279(18):18392-400. Epub 2004 Feb 17.


Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton.

Krendel M, Zenke FT, Bokoch GM.

Nat Cell Biol. 2002 Apr;4(4):294-301.


Supplemental Content

Loading ...
Support Center